Hendrik Ruge

Showing 1-3 of 3 articles

Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study

Manoharan G, Grube E, Van Mieghem N, Brecker S, Fiorina C, Kornowski R, Danenberg H, Ruge H, Thiele H, Lancellotti P, Søndergaard L, Tamburino C, Oh J, Fan Y, Windecker S

November 20, 2020 | 10.4244/EIJ-D-20-00279

Clinical experience with a novel large bore vascular closure device after transfemoral transcatheter aortic valve replacement

Ruge H, Erlebach M, Mayr P, Bleiziffer S, Lange R

June 25, 2020 | 10.4244/EIJ-D-19-00523

Interventions for valvular disease

Beyond the five-year horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices

Deutsch M-A, Erlebach M, Burri M, Hapfelmeier A, Witt OG, Ziegelmueller JA, Wottke M, Ruge H, Krane M, Piazza N, Bleiziffer S, Lange R

May 20, 2018 | 10.4244/EIJ-D-17-00603

1

Latest news

A State of the Art on cardiogenic shock; a trial of balloon-based techniques for calcified lesions; a mini focus on spontaneous coronary artery dissection, and more…

August 27, 2021

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

New European insights on SCAD: are we any closer in our scientific exploration voyage?

Jacqueline Saw et al

August 27, 2021

Severely calcified coronary stenoses: a war or a battle?

Emanuele Barbato et al

September 3, 2021

ESC LATEST SCIENCE

TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

George Dangas et al

August 26, 2021

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

Dabigatran-based dual antithrombotic therapy for patients with AF and STEMI undergoing pci

Dominick J. Angiolillo et al

August 27, 2021

Valvular disease